Immunomodulatory thymic peptide

Thymosin Alpha-1

Immunity

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide that modulates immune responses. It has been studied in infections, cancer support and sepsis, but findings are indication-specific and do not support generic ‘immune boosting’.

1Overview
2× / wkReference frequency
DataExtensive clinical research with varied indications and quality
Research status

Approved for specific indications in several countries; not universally

Velora Thymosin Alpha-1 vial
THYMOSIN ALPHA-110 MG
01 · Overview

What is Thymosin Alpha-1?

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide that modulates immune responses. It has been studied in infections, cancer support and sepsis, but findings are indication-specific and do not support generic ‘immune boosting’.

Research route, formulation and population determine what a result actually means.

01

Immunity

Thymosin-α1 modulates innate and adaptive immune responses.

02 · Research

What do the studies show?

Extensive clinical research with varied indications and quality. Educational information. Not diagnosis, treatment or use advice.

Phase 3
Phase 3

TESTS sepsis trial

A large double-blind phase 3 trial found no convincing overall mortality benefit; subgroup findings are hypothesis-generating.

Mixed
Limited evidence

Indications differ

Results from hepatitis, cancer or sepsis studies cannot be extrapolated to healthy people or other diseases.

03 · DATA

Peptide and product specifications

Checked identity data for this research compound or blend.

Thymosin Alpha-1Peptide and product specifications
Molecular formula
C₁₂₉H₂₁₅N₃₃O₅₅
Molecular weight
3108.3 g/mol
CAS number
62304-98-7
Amino-acid sequence / components
Ac-SDAAVDTSSEITTKDLKEKKEVEEEAEN
Amino-acid count
28
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference form
White lyophilised powder
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data

These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.

04 · Calculator

Reconstitution and U-100 conversion

This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.

Calculator

Twice weekly in many clinical studies

1
2
3
4
Draw to
0 units
0.00 mL
Thymosin Alpha-1 vial
THYMOSIN ALPHA-1
10 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION

How to reconstitute Thymosin Alpha-1 for laboratory research

A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.

Five visual laboratory reconstitution steps: clean, measure diluent, add slowly, swirl gently and store according to protocol.
1

Clean

Disinfect the rubber closures of both vials and allow them to dry.

2

Measure diluent

Withdraw only the diluent validated for the specific compound.

3

Add slowly

Let the liquid run slowly down the inside wall of the vial.

4

Swirl gently

Do not shake; rotate gently until the material has dissolved.

5

Store per protocol

Follow the product label, COA and validated stability data.

Important checks before and after reconstitution

Check the product

First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.

Use clean, sterile technique

Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.

Concentration, not total amount

The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.

Inspect and label

Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.

General reconstitution volumes listed by the source

General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.

Vial strengthCommonly listed volume
2 mg1–2 mL
5 mg2–3 mL
6 mg2–3 mL
10 mg2–4 mL
15 mg3–5 mL
20 mg4–8 mL

Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.

05 · Safety and limitations

Safety and limitations

Research route, formulation and population determine what a result actually means.

What is known

  • Visible research claims use primary or official sources.
  • The calculator is arithmetic and does not turn a study amount into medical advice.
  • A registered medicine and a research vial are not automatically equivalent.

What remains uncertain

  • Many products lack long-term safety data and independent replication.
  • Animal and cell findings do not predict a safe human dose.
  • Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Approved for specific indications in several countries; not universally. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ

Frequently asked questions

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide that modulates immune responses. It has been studied in infections, cancer support and sepsis, but findings are indication-specific and do not support generic ‘immune boosting’.
A large double-blind phase 3 trial found no convincing overall mortality benefit; subgroup findings are hypothesis-generating. Results from hepatitis, cancer or sepsis studies cannot be extrapolated to healthy people or other diseases.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources

Primary research sources

Educational information. Not diagnosis, treatment or use advice.

Thymosin α1 for sepsis: multicentre randomised phase 3 TESTS trial BMJ, 2025. Link
Thymosin alpha 1 clinical trials - indexed primary literature PubMed, 2026. Link